NRP1 and COVID-19: By antagonizing the docking of VEGF-A to NRP-1, it may be presumed that the S protein could potentially disrupt physiological pathways involved in angiogenesis and nociception [8,27,28,29], contributing to the neurological and cardiovascular manifestations seen in SARS-CoV-2-infected individuals as well as in some COVID-19 vaccine recipients.